523 related articles for article (PubMed ID: 17056720)
1. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
[TBL] [Abstract][Full Text] [Related]
2. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
[TBL] [Abstract][Full Text] [Related]
3. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
[TBL] [Abstract][Full Text] [Related]
4. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
5. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
Nunn C; Langenegger D; Hurth K; Schmidt K; Fehlmann D; Hoyer D
Eur J Pharmacol; 2003 Apr; 465(3):211-8. PubMed ID: 12681432
[TBL] [Abstract][Full Text] [Related]
6. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
7. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues.
Waser B; Tamma ML; Cescato R; Maecke HR; Reubi JC
J Nucl Med; 2009 Jun; 50(6):936-41. PubMed ID: 19443580
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
Cescato R; Waser B; Fani M; Reubi JC
J Nucl Med; 2011 Dec; 52(12):1886-90. PubMed ID: 22068898
[TBL] [Abstract][Full Text] [Related]
9. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.
Cescato R; Erchegyi J; Waser B; Piccand V; Maecke HR; Rivier JE; Reubi JC
J Med Chem; 2008 Jul; 51(13):4030-7. PubMed ID: 18543899
[TBL] [Abstract][Full Text] [Related]
10. First clinical evidence that imaging with somatostatin receptor antagonists is feasible.
Wild D; Fani M; Behe M; Brink I; Rivier JE; Reubi JC; Maecke HR; Weber WA
J Nucl Med; 2011 Sep; 52(9):1412-7. PubMed ID: 21852357
[TBL] [Abstract][Full Text] [Related]
11. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
12. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.
Wang X; Fani M; Schulz S; Rivier J; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1876-85. PubMed ID: 22926735
[TBL] [Abstract][Full Text] [Related]
14. A new
Mansi R; Abid K; Nicolas GP; Del Pozzo L; Grouzmann E; Fani M
EJNMMI Res; 2020 Aug; 10(1):90. PubMed ID: 32757150
[TBL] [Abstract][Full Text] [Related]
15. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
17. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.
Wild D; Fani M; Fischer R; Del Pozzo L; Kaul F; Krebs S; Fischer R; Rivier JE; Reubi JC; Maecke HR; Weber WA
J Nucl Med; 2014 Aug; 55(8):1248-52. PubMed ID: 24963127
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
19. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
